First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies

被引：26

作者：

Morikawa, Naoto ^{[1
]}

Minegishi, Yuji ^{[2
]}

Inoue, Akira ^{[3
]}

Maemondo, Makoto ^{[4
]}

Kobayashi, Kunihiko ^{[5
]}

Sugawara, Shunichi ^{[6
]}

Harada, Masao ^{[7
]}

Hagiwara, Koichi ^{[5
]}

Okinaga, Shoji ^{[3
]}

Oizumi, Satoshi ^{[8
]}

Nukiwa, Toshihiro ^{[9
]}

Gemma, Akihiko ^{[2
]}

机构：

[1] Iwate Med Univ, Sch Med, Div Pulm Med Allergy & Rheumatol, Dept Internal Med, Morioka, Iwate 0208505, Japan

[2] Nippon Med Sch, Tokyo 113, Japan

[3] Tohoku Univ, Sendai, Miyagi 980, Japan

[4] Miyagi Canc Ctr, Natori, Miyagi, Japan

[5] Saitama Med Univ, Moroyama, Saitama, Japan

[6] Sendai Kousei Hosp, Sendai, Miyagi, Japan

[7] Natl Hosp Org, Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan

[8] Hokkaido Univ, Sapporo, Hokkaido 060, Japan

[9] AntiTB Assoc, Tokyo, Japan

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2015年 / 16卷 / 04期

关键词：

EGFR tyrosine kinase inhibitors; elderly patients; gefitinib; NSCLC; CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; OPEN-LABEL; CARBOPLATIN-PACLITAXEL; PHASE-III; CHEMOTHERAPY; ERLOTINIB; MULTICENTER; SURVIVAL; TRIAL;

D O I：

10.1517/14656566.2015.1002396

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective: To assess outcomes of elderly patients with advanced NSCLC harboring an EGFR mutation treated with gefitinib, as well as safety and impact on quality of life (QoL). Methods: We performed a retrospective analysis of pooled data from one Phase III and two Phase II studies of 71 patients aged >= 70 years with a performance status of 0-2. The main outcome measures were progression-free survival (PFS), overall survival (OS) and response rate (RR), as well as incidence of adverse events and time to 9.1% deterioration in QoL. Results: Median PFS (14.3 vs 5.7 months, p < 0.001) and overall RR (73.2 vs 26.5%, p < 0.001) in the gefitinib group were superior to those in the standard chemotherapy group, whereas median OS was not significantly different (30.8 vs 26.4 months, p = 0.42). Elevation of aspartate transaminase and/or alanine transaminase (18.3%) was the most common adverse event, and one treatment-related death (pneumonitis) occurred. Time to 9.1% deterioration in the QoL domains of pain and dyspnea, anxiety, and daily functioning was similar between the two age groups. Conclusion: First-line gefitinib is efficacious with acceptable toxicity in relatively fit elderly patients with advanced NSCLC harboring an EGFR mutation.

引用

页码：465 / 472

页数：8

共 20 条

[1] Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE):: A randomized, phase II study [J].

Crino, Lucio ;

Cappuzzo, Federico ;

Zatloukal, Petr ;

Reck, Martin ;

Pesek, Milos ;

Thompson, Joyce C. ;

Ford, Hugo E. R. ;

Hirsch, Fred R. ;

Varella-Garcia, Marileila ;

Ghiorghiu, Serban ;

Duffield, Emma L. ;

Armour, Alison A. ;

Speake, Georgina ;

Cullen, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) :4253-4260

[2] Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS) [J].

Fukuoka, Masahiro ;

Wu, Yi-Long ;

Thongprasert, Sumitra ;

Sunpaweravong, Patrapim ;

Leong, Swan-Swan ;

Sriuranpong, Virote ;

Chao, Tsu-Yi ;

Nakagawa, Kazuhiko ;

Chu, Da-Tong ;

Saijo, Nagahiro ;

Duffield, Emma L. ;

Rukazenkov, Yuri ;

Speake, Georgina ;

Jiang, Haiyi ;

Armour, Alison A. ;

To, Ka-Fai ;

Yang, James Chih-Hsin ;

Mok, Tony S. K. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) :2866-2874

[3] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) [J].

Inoue, A. ;

Kobayashi, K. ;

Maemondo, M. ;

Sugawara, S. ;

Oizumi, S. ;

Isobe, H. ;

Gemma, A. ;

Harada, M. ;

Yoshizawa, H. ;

Kinoshita, I. ;

Fujita, Y. ;

Okinaga, S. ;

Hirano, H. ;

Yoshimori, K. ;

Harada, T. ;

Saijo, Y. ;

Hagiwara, K. ;

Morita, S. ;

Nukiwa, T. .

ANNALS OF ONCOLOGY, 2013, 24 (01) :54-59

[4] First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy [J].

Inoue, Akira ;

Kobayashi, Kunihiko ;

Usui, Kazuhiro ;

Maemondo, Makoto ;

Okinaga, Shoji ;

Mikami, Iwao ;

Ando, Masahiro ;

Yamazaki, Koichi ;

Saijo, Yasuo ;

Gemma, Akihiko ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Ikebuchi, Kenji ;

Nukiwa, Toshihiro ;

Morita, Satoshi ;

Hagiwara, Koichi .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1394-1400

[5] Phase II clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer [J].

Jackman, David M. ;

Yeap, Beow Y. ;

Lindeman, Neal I. ;

Fidias, Panos ;

Rabin, Michael S. ;

Temel, Jennifer ;

Skarin, Arthur T. ;

Meyerson, Matthew ;

Holmes, Alison J. ;

Borras, Ana M. ;

Freidlin, Boris ;

Ostler, Patricia A. ;

Lucca, Joan ;

Lynch, Thomas J. ;

Johnson, Bruce E. ;

Jaenne, Pasi A. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :760-766

[6] Interstitial lung disease in Japanese patients with lung cancer - A cohort and nested case-control study [J].

Kudoh, Shoji ;

Kato, Harubumi ;

Nishiwaki, Yutaka ;

Fukuoka, Masahiro ;

Nakata, Kouichiro ;

Ichinose, Yukito ;

Tsuboi, Masahiro ;

Yokota, Soichiro ;

Nakagawa, Kazuhiko ;

Suga, Moritaka ;

Jiang, Haiyi ;

Itoh, Yohji ;

Armour, Alison ;

Watkins, Claire ;

Higenbottam, Tim ;

Nyberg, Fredrik .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (12) :1348-1357

[7] Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis [J].

Lee, Chee Khoon ;

Brown, Chris ;

Gralla, Richard J. ;

Hirsh, Vera ;

Thongprasert, Sumitra ;

Tsai, Chun-Ming ;

Tan, Eng Huat ;

Ho, James Chung-Man ;

Chu, Da Tong ;

Zaatar, Adel ;

Osorio Sanchez, Jemela Anne ;

Vu Van Vu ;

Au, Joseph Siu Kie ;

Inoue, Akira ;

Lee, Siow Ming ;

Gebski, Val ;

Yang, James Chih-Hsin .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (09) :595-605

[8] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[9] First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations NEJ 003 Study [J].

Maemondo, Makoto ;

Minegishi, Yuji ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Harada, Masao ;

Okinaga, Shoji ;

Morikawa, Naoto ;

Oizumi, Satoshi ;

Tanaka, Tomoaki ;

Isobe, Hiroshi ;

Kudoh, Shoji ;

Hagiwara, Koichi ;

Nukiwa, Toshihiro ;

Gemma, Akihiko .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) :1417-1422

[10] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].

Maemondo, Makoto ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Sugawara, Shunichi ;

Oizumi, Satoshi ;

Isobe, Hiroshi ;

Gemma, Akihiko ;

Harada, Masao ;

Yoshizawa, Hirohisa ;

Kinoshita, Ichiro ;

Fujita, Yuka ;

Okinaga, Shoji ;

Hirano, Haruto ;

Yoshimori, Kozo ;

Harada, Toshiyuki ;

Ogura, Takashi ;

Ando, Masahiro ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Saijo, Yasuo ;

Hagiwara, Koichi ;

Morita, Satoshi ;

Nukiwa, Toshihiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388

← 1 2 →